Safety and immunogenicity of the ChAdOx1-MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK
在英国开展的HIV-CORE 005.2研究中，一项针对未感染HIV-1的成年人的开放标签、剂量递增、首次人体I期试验，评估了ChAdOx1-MVA载体保守嵌合HIVconsvX候选T细胞疫苗的安全性和免疫原性。
期刊:Lancet Microbe
影响因子:
doi:10.1016/j.lanmic.2024.100956
Borthwick, Nicola; Fernandez, Natalia; Hayes, Peter J; Wee, Edmund G-T; Akis Yildirim, Belkis M; Baines, Andrea; Baker, Megan; Byard, Nicholas; Conway, Oliver; Glaze, Molly; Jenkin, Daniel; Larkworthy, Colin; Luciw, Michael; Platt, Abigail; Poulton, Ian; Thomas, Merin; Quaddy, Jack; Watson, Marion; Crook, Alison; Cicconi, Paola; Hanke, Tomáš
T细胞
HIV
炎症/感染
微生物学
T细胞
细胞生物学
免疫/内分泌
